Richard Harris

Award-winning journalist Richard Harris has reported on a wide range of topics in science, medicine and the environment since he joined NPR in 1986. In early 2014, his focus shifted from an emphasis on climate change and the environment to biomedical research.

Harris has traveled to all seven continents for NPR. His reports have originated from Timbuktu, the South Pole, the Galapagos Islands, Beijing during the SARS epidemic, the center of Greenland, the Amazon rain forest, the foot of Mt. Kilimanjaro (for a story about tuberculosis), and Japan to cover the nuclear aftermath of the 2011 tsunami.
In 2010, Harris' reporting revealed that the blown-out BP oil well in the Gulf of Mexico was spewing out far more oil than asserted in the official estimates. That revelation led the federal government to make a more realistic assessment of the extent of the spill.

Harris covered climate change for decades. He reported from the United Nations climate negotiations, starting with the Earth Summit in Rio de Janeiro in 1992, and including Kyoto in 1997 and Copenhagen in 2009. Harris was a major contributor to NPR's award-winning 2007-2008 "Climate Connections" series.

Over the course of his career, Harris has been the recipient of many prestigious awards. Those include the American Geophysical Union's 2013 Presidential Citation for Science and Society. He shared the 2009 National Academy of Sciences Communication Award and was a finalist again in 2011. In 2002, Harris was elected an honorary member of Sigma Xi, the scientific research society. Harris shared a 1995 Peabody Award for investigative reporting on NPR about the tobacco industry. Since 1988, the American Association for the Advancement of Science has honored Harris three times with its science journalism award.

Before joining NPR, Harris was a science writer for the San Francisco Examiner. From 1981 to 1983, Harris was a staff writer at The Tri-Valley Herald in Livermore, California, covering science, technology, and health issues related to the nuclear weapons lab in Livermore. He started his career as an AAAS Mass Media Science Fellow at the now-defunct Washington (DC) Star.

Harris is co-founder of the Washington, D.C., Area Science Writers Association, and is past president of the National Association of Science Writers. He serves on the board of the Council for the Advancement of Science Writing.

A California native, Harris returned to the University of California-Santa Cruz in 2012, to give a commencement address at Crown College, where he had given a valedictory address at his own graduation. He earned a bachelor's degree at the school in biology, with highest honors.

Researchers are developing a radical way to diagnose infectious diseases. Instead of guessing what a patient might have, and ordering one test after another, this new technology starts with no assumptions.

The technology starts with a sample of blood or spinal fluid from an infected person and searches through all the DNA in it, looking for sequences that came from a virus, a bacterium, a fungus or even a parasite.

News about cancer therapies usually comes out in medical journals with the regular rhythm of an IV drip. But every now and then information comes out in a flood.

That's the case this weekend. The American Society of Clinical Oncology is holding its 50th annual meeting in Chicago. The convention typically attracts 30,000 attendees, making it one of the biggest cancer meetings of the year. And the amount of new information must be bewildering for even the most intrepid doctors.

Members of Amish communities in Ohio traveled to the Philippines for heartfelt reasons: They were there on service projects to help less fortunate people. Unfortunately, they came home with unwelcome hitchhikers: measles viruses.

Those travelers hadn't been vaccinated against this highly contagious disease, the Centers for Disease Control and Prevention said Thursday. As a result, they have triggered an outbreak of more than 130 cases, primarily among their unvaccinated friends and relatives in Amish communities.

For the first time in decades, researchers trying to develop a vaccine for malaria have discovered a new target they can use to attack this deadly and common parasite.

Finding a target for attack is a far cry from having a vaccine. And the history of malaria vaccines is littered with hopeful ideas that didn't pan out. Still, researchers in the field welcome this fresh approach.

Many potential new drugs look like they could be big winners — at least when judged by how well they work in mice or other lab animals. Over the years, there have been a number of promising cancer "cures," possible Alzheimer's treatments, and candidate drugs for holding back the ravages of various degenerative diseases.

But, time after time, these great promises fade away once the potential treatments are tried in people. There are lots of reasons for that. Humans aren't rodents, for starters.

When you think of bird flu, you may conjure up images of chickens being slaughtered to stem an outbreak, or of migrating ducks, which can carry flu viruses from one continent to the next. Well, it's time to add penguins to your list of mental images.

Yes, Adelie penguins, which breed in huge colonies on the rocky Antarctic Peninsula, also harbor a version of the avian influenza virus, according to a study published in the journal, mBio.

Whooping cough was once one of the leading killers of babies around the world. Now that it's largely controlled with a vaccine, scientists have had a chance to figure out how the disease came into being in the first place.

That story is told in a study published online this week in the journal mBio. And it turns out that whooping cough arose quite late in human history.

Eighteen years ago, scientists in Scotland took the nuclear DNA from the cell of an adult sheep and put it into another sheep's egg cell that had been emptied of its own nucleus. The resulting egg was implanted in the womb of a third sheep, and the result was Dolly, the first clone of a mammal.

Dolly's birth set off a huge outpouring of ethical concern — along with hope that the same techniques, applied to human cells, could be used to treat myriad diseases.

The Ebola outbreak in West Africa is terrifying because there's no drug to treat this often fatal disease. But the disease is so rare, there's no incentive for big pharmaceutical companies to develop a treatment.

Even so, some small companies, given government incentives, are stepping into that breach. The result: More than half a dozen ideas are being pursued actively.

Most experimental drugs fail before they make it through all the tests required to figure out if they actually work and if they're safe. But some drugs get fairly far down that road, at the cost of hundreds of millions of dollars, based on poorly conducted studies at the outset.

Medical researchers reviewing this sorry state of affairs say the drug-development process needs serious improvement.

One of these days, there could well be a simple blood test that can help diagnose and track cancers. We aren't there yet, but a burst of research in this area shows we are getting a lot closer.

In the latest of these studies, scientists have used blood samples to identify people with lung cancer.

Using the labor of dozens of undergraduate students, scientists have built a customized yeast chromosome from scratch.

It's a milestone in the rapidly growing field of synthetic biology, where organisms can be tailored for industrial use. In this case, the near-term goal is to understand the genetics of yeast, and eventually the genetics of us.

This was quite an undertaking. Yeast have about 6,000 genes packed in 16 tidy bundles called chromosomes. Each chromosome is an enormous molecule of DNA packed in proteins.

Hospital-acquired infections continue to be a big problem in health care, with 4 percent of patients getting a new infection while hospitalized, a study finds. And 11 percent of those infections turn deadly.

It's the first time that the Centers for Disease Control and Prevention has attempted to catalog all hospital infections, not just the infections with germs on their watch list. Researchers surveyed 183 hospitals nationwide, emphasizing smaller community hospitals.

The human eye can distinguish more than 2 million distinct colors. But scientists studying smell now say they have their vision colleagues beat: The human nose, they say, can distinguish more than a trillion different smells.

Yes, trillion with a T.

That new figure displaces a much more modest estimate. Until now, smell researchers have been saying the human nose can distinguish about 10,000 smells.

If you want to know what's up with the flu at the moment, you have a few choices: You can get the latest information at Google Flu Trends. Or you can get the official word from the Centers for Disease Control and Prevention, which is based on data that's by now a couple of weeks old.

But a report in the journal Science finds that quicker isn't necessarily better.

Pages